tradingkey.logo

Avidity Biosciences Receives FDA Breakthrough Therapy Designation For Duchenne Muscular Dystrophy Treatment

ReutersJul 23, 2025 1:10 PM

- Avidity Biosciences Inc RNA.O:

  • AVIDITY BIOSCIENCES RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR DELPACIBART ZOTADIRSEN (DEL-ZOTA) FOR THE TREATMENT OF DMD IN PEOPLE WITH MUTATIONS AMENABLE TO EXON 44 SKIPPING

  • AVIDITY BIOSCIENCES INC - ON TRACK FOR BLA SUBMISSION FOR DEL-ZOTA BY YEAR-END 2025

  • AVIDITY BIOSCIENCES INC - DEL-ZOTA SHOWS SIGNIFICANT INCREASES IN EXON SKIPPING AND DYSTROPHIN

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI